Compositions for medical implantation

Details Compositions for medical implantation Compositions for medical implantation

2001-02-16

2003-01-21

Isabella, David J. (Department: 3738)

Prosthesis (i.e., artificial body members), parts thereof, or ai

Implantable prosthesis

C623S023760, C623S023570

Reexamination Certificate

active

06508838

ABSTRACT:

FIELD OF THE INVENTION
This invention is predicated upon the discovery that tartrate-resistant acid phosphatase (TRAP) is a potent differentiating factor for osteoclasts. The invention provides, in the presently claimed embodiment, TRAP-coated bone grafts and implantable permanent orthopedic and dental prostheses.
BACKGROUND OF THE INVENTION
TRAP, also known as uteroferrin (12; see the appended Citations), purple acid phosphatase (13), or type 5 acid phosphatase (14-16), is an iron-containing, cationic glycoprotein with a molecular weight of about 35 kDa. A variety of organs including bone, spleen, lung, placenta, the pregnant pig uterus and certain leukemic cells express this enzyme (12-17). TRAP enzyme activity is detected in blood and a high enzyme level reflects active bone remodeling (18,19). In bone, the enzyme is highly expressed by multinuclear osteoclasts and mononuclear cells thought to be osteoclasts or osteoclast precursors (
15
). The high level of expression by osteoclasts and TRAP concentration in cytoplasmic vacuoles, extracellular channels, ruffled borders and at the cell-bone interface have implicated the enzyme in bone matrix degradation (
20
). The function of TRAP, however, is still unknown. A blocking antibody to porcine uteroferrin markedly inhibited both the enzyme activity and bone resorption by osteoclasts in vitro (
21
). Several reports point to a role for TRAP in bone remodeling. Knock-out mice lacking TRAP, generated by the homologous recombination technique, showed abnormal endochondral ossification of bones and an unusual form of mild osteopetrosis (
22
). A number of studies have shown that M-CSF plays a critical role in both macrophage and osteoclast maturation and function (
3
).
Osteoclasts, the cells that resorb bone, are essential for normal skeletal growth and remodeling. They are derived from hematopoietic progenitor/stem cells of the granulocyte/macrophage lineage, but the exact point of their divergence is controversial (
1
,
2
). While recent studies have revealed several factors involved in cell-to-cell interactions in development of osteoclast function (
3
,
4
), regulation of osteoclast progenitor differentiation and recruitment to a bone surface for resorption is still poorly understood. Better understanding of the molecular mechanisms of osteoclast differentiation and recruitment could lead to novel diagnostics and therapeutics for use in the prevention and management of osteoporosis, a common disease that results from a net imbalance between bone resorption and bone formation in the adult skeleton. This imbalance can widen when resorption accelerates after menopause associated with an increase in osteoclast numbers and resorptive activity. It is also known that certain carcinomas are prone to metastasize to bone and/or can release factors locally or systemically that promote osteolysis (bone resorption). The molecular and cellular bases of such tumor properties are not fully understood.
SUMMARY OF THE INVENTION
The invention provides, in the presently claimed embodiment, a composition or device suitable for orthopedic or dental implantation to bone, characterized by tartrate-resistant acid phosphatase (TRAP) adsorbed to a porous hydroxyapatite substratum. Such implants include autologous bone grafts, cadaveric bone allografts, hydroxyapatite-containing bone cements, prosthetic devices such as artificial joints and teeth having hydroxyapatite-coated bone attachment surfaces, and orthopedic attachment devices such as staples and plates having hydroxyapatite-coated bone contacting surfaces.
Upon implantation, the TRAP coating serves to recruit or attract osteoclast progenitor cells from the bone marrow or bloodstream to the bone implant or hydroxyapatite surface of the prosthetic or attachment device. The recruited osteoclast population etches the bone mineral or hydroxyapatite surface of the implant and thereby provides the natural signals to recruit osteoblasts to lay down new bone that will abut and integrate with the graft or prosthetic surface mimicking the natural process of bone deposition on an osteoclast resorbed bone surface. The TRAP-induced stimulation of osteoclast recruitment results in osteointegration and enhanced bonding of the graft or prosthesis to the patient's bone. This reduces recovery time from the operation and lengthens the life of implants by reducing their well-documented tendency to loosen over several years. Bone grafts also are integrated more effectively mechanically and biologically into living bone at the implant site.


REFERENCES:
patent: 5073114 (1991-12-01), Detsch
patent: 5162430 (1992-11-01), Rhee et al.
patent: 5226914 (1993-07-01), Caplan et al.
patent: 5258029 (1993-11-01), Chu et al.
patent: 5258367 (1993-11-01), Bazer et al.
patent: 5591453 (1997-01-01), Ducheyne et al.
patent: 5654173 (1997-08-01), Jacobs et al.
patent: 5824087 (1998-10-01), Aspden et al.
patent: 5854207 (1998-12-01), Lee et al.
patent: 5876446 (1999-03-01), Agrawal et al.
patent: 5879663 (1999-03-01), Nakabayashi et al.
patent: 6190412 (2001-02-01), Lee et al.
patent: WO 93/00935 (1993-01-01), None
patent: WO 93/07271 (1993-04-01), None
Ling, P., and Roberts, R.M., “Uteroferrin and Intracellular Tartrate-resistant Acid Phosphatases Are the Products of the Same Gene,”J. Biol. Chem.268:6896-6902, 1993.
Hayman, A.R., and Cox, T.M., “Purple Acid Phosphatase of the Human Macrophage and Osteoclast,”J. Biol. Chem.269:1294-1300, 1994.
Ketcham, C.M., et al., “Molecular Cloning of the Type 5, Iron-containing, Tartrate-resistant Acid Phosphatase from Human Placenta,”J. Biol. Chem.264:557-563, 1989.
Ek-Rylander, B., et al., “Cloning, Sequence, and Developmental Expression of a Type 5, Tartrate-resistant, Acid Phosphatase of Rate Bone,”J. Biol. Chem.266:24684-24689, 1991.
Ek-Rylander, B., et al., “Comparative studies of rat recombinant purple acid phosphatase and bone tartrate-resistant acid phosphatase,”Biochem. J.321:305-311, 1997.
Yam, L.T., et al., “Tartrate-Resistant Acid Phosphatase Isoenzyme in the Reticulum Cells of Leukemic Reticuloendotheliosis,”N. Engl. J. Med.284:357-360, 1971.
Lau, K.H., et al., “Characterization and Assay of Tartrate-Resistant Acid Phosphatase Activity in Serum: Potential Use to Assess Bone Resorption,”Clin. Chem.33:458-462, 1987.
Chamberlain, P., et al., “Generation and Characterization of Monoclonal Antibodies to Human Type-5 Tartrate-Resistant Acid Phosphatase: Development of a Specific Immunoassay of the Isoenzyme in Serum,”Clin. Chem.41:1495-1499, 1995.
Reinholt, F., et al., “Ultrastructural Localization of a Tartrate Resistant Acid ATPase in Bone,”J. Bone Miner. Res.5:1055-1061, 1990.
Zaidi, M., et al., “Inhibition of Osteoclastic Acid Phosphatase Abolishes Bone Resportion,”Biochem. Biophys. Res. Commun.159:68-71, 1989.
Hayman, A.R., et al., “Mice lacking tartrate-resistant acid phosphatase (Acp 5) have disrupted endochondral ossification and mild osteopetrosis,”Development122:3151-3162, 1996.
Suda, T., et al., “Modulation of Osteclast Differentiation,”Endocrine Reviews13:66-80, 1992.
Roodman, G.D., “Advances in bone biology: The osteoclast,”Endocrine Reviews17:308-332, 1996.
Suda, T., et al., “Modulation of Osteoclast Differentiation by Local Factors,”Bone17(2S):87S-91S, 1995.
Yasuda, H., et al., “Osteoclast differentiation factor is a ligand for osteoprotegerin/osteoclastogenesis-inhibitory factor and is identical to TRANCE/RANKL,”Proc. Natl. Acad. Sci. USA95:3597-3602, 1998.
Roach, H.I., “New Aspects of Endochrondral Ossification in the Chick: Chondrocyte Apoptosis, Bone Formation by Former Chondrocytes, and Acid Phosphatase Activity in the Endochondral Bone Matrix,”J. Bone Miner. Res.12:795-805, 1997.
Yamamoto, T. and Nagai, H., “A Histochemical Study of Acid Phosphatases in Medullary Bone Matrix and Osteoclasts in Laying Japanese Quail,”J. Bone Miner. Res.7:1267-1273, 1992.
Yamamoto, T. and Nagai, H., “Tartrate-resistant acid phosphatase accumulated in the matrix of developing medullary bone induced by estrogen treatment of male Japanese quail,”J. Bone Mier. Res.9:1153-1157 (Abstract)

Affiliated with

Also associated with

Rating

Compositions for medical implantation does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Compositions for medical implantation, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Compositions for medical implantation will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-3070979